Recently, PD-1/PD-L1 antagonists based on small molecular peptides have received much attention due to the advantages of lower manufacturing cost, modifiable structure, tumor penetration, and reduced immunogenicity 36, 37. Here, PDCD1 is linked to neoplasm.